Whole brain modelling for simulating pharmacological interventions on patients with disorders of consciousness.
Iván Mindlin, Rubén Herzog, Laouen Belloli, Dragana Manasova, M Monge-Asensio, Jakub Vohryzek, Anira Escrichs, Naji Alnagger, Pablo Núñez, Olivia Gosseries, M L Kringelbach, Gustavo Deco, Enzo Tagliazucchi, Lionel Naccache, Benjamin Rohaut, J D Sitt, Yonatan Sanz Perl
Communications Biology September 19, 2024 DOI: 10.1038/s42003-024-06852-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Computational modeling study Peer reviewed |
|---|---|
| Population | Biologically plausible whole-brain models of patients with disorders of consciousness |
| Citations | 18 |
| Key points | Simulated activation of serotonergic and opioid receptors shifted whole-brain models of disorders of consciousness toward dynamics associated with healthier states, with improvements correlated to mean receptor density. |
Abstract
Disorders of consciousness (DoC) represent a challenging and complex group of neurological conditions characterised by profound disturbances in consciousness. The current range of treatments for DoC is limited. This has sparked growing interest in developing new treatments, including the use of psychedelic drugs. Nevertheless, clinical investigations and the mechanisms behind them are methodologically and ethically constrained. To tackle these limitations, we combined biologically plausible whole-brain models with deep learning techniques to characterise the low-dimensional space of DoC patients. We investigated the effects of model pharmacological interventions by including the whole-brain dynamical consequences of the enhanced neuromodulatory level of different neurotransmitters, and providing geometrical interpretation in the low-dimensional space. Our findings show that serotonergic and opioid receptors effectively shifted the DoC models towards a dynamical behaviour associated with a healthier state, and that these improvements correlated with the mean density of the activated receptors throughout the brain. These findings mark an important step towards the development of treatments not only for DoC but also for a broader spectrum of brain diseases. Our method offers a promising avenue for exploring the therapeutic potential of pharmacological interventions within the ethical and methodological confines of clinical research.
Citations in the library
Cited by 8
- The Algorithmic Agent Perspective and Computational Neuropsychiatry: From Etiology to Advanced Therapy in Major Depressive Disorder Entropy November 6, 2024
- Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues. Expert Review of Neurotherapeutics June 1, 2025
- A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness Advanced Science November 20, 2025
- Structural determinants of dynamical state transitions in disorders of consciousness: a whole-brain modeling approach bioRxiv (Cold Spring Harbor Laboratory) July 1, 2026
- If the code hurts: on pain and virtual brains AI and Ethics April 27, 2026
and 3 more in the library
Cites 24
- Neural correlates of consciousness: progress and problems Nature Reviews Neuroscience April 20, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Frontiers in Human Neuroscience 2014
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
and 19 more in the library